Kornimate/medical-research-clean huggingface dataset:
liraglutide in acute minor ischemic stroke or high-risk transient ischemic attack patients with type 2 diabetes mellitus

Conditions: Ischemic Stroke; Transient Ischemic Attack; Type 2 Diabetes Mellitus

Summary: the purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1 (glp-1) analogue liraglutide in the treatment of acute minor stroke (national institute of health stroke scale, nihss ≤ 3) or high-risk transient ischemic attack (tia) (abcd2 score ≥ 4 ) patients with type 2 diabetes mellitus.

the treatment arm will receive the starting dose of liraglutide of 0.6mg/d subcutaneously once daily, and the dose will be increased to 1.8mg/d in two weeks, and then continue to administrate this dose for 90 days. the control arm will not use liraglutide. other types of glp-1 analogues or degraded by dipeptidyl peptidase-iv (dpp-iv) inhibitors will be prohibited. study visits will be performed at day 7, day 30±3 and at 90±7 day.

Eligibility criteria:
inclusion criteria: * adult subjects (male or female ≥ 50 years); * acute ischemic stroke patients (nihss ≤ 3 at the time of randomization) with type 2 diabetes mellitus within 24 hours of symptoms onset; * high-risk tia patients (abcd2 score ≥ 4 at the time of randomization) with type 2 diabetes mellitus within 24 hours of onset; * first stroke, or prior stroke without sequel (mrs score ≤ 1) and does not affect the nihss score; * informed consent signed. exclusion criteria: * diagnosis of hemorrhage brain disease on baseline head ct; * iatrogenic and cardiogenic stroke; * patients receiving thrombolysis or endovascular treatment; * use of a glp-1 analogue or any dipeptidyl peptidase-iv (dpp-iv) inhibitor within the 3 months prior to screening; * family or personal history of multiple endocrine neoplasia type 2 (men2) or familial medullary thyroid carcinoma (fmtc); * patients with pancreatitis or previous history of pancreatitis, inflammatory bowel disease and gastroparesis; * pregnant, lactating women,or patients who are likely to have a pregnancy and plan to have one; * allergic to liraglutide or excipients; * congestive heart failure (nyha class iii-iv); * severe liver and kidney dysfunction (ast/alt is 3 times higher than the normal upper limit, serum creatinine is 3 times higher than the normal upper limit); * patients with malignant tumors who are expected to have a survival period of less than three months; * participated in other clinical trials of drugs within 3 months; * researchers believe that patients who are not suitable for this clinical study.

Keywords: ischemic stroke transient ischemic attack glucagon-like peptide-1 type 2 diabetes mellitus
tailored juice-guided eradication therapy

Conditions: Helicobacter Pylori Infection

Summary: in this study, the investigators aim to investigate the efficacy of tailored anti-microbial susceptibility guided-therapy via gastric juice pcr, compared with empirical standard triple therapy.

the eradication of h. pylori is an important clinical issue due to its association with many gastrointestinal diseases such as peptic ulcer and even gastric cancer. however, with the global trend of increasing antibiotic resistance, the eradication rate of clarithromycin-based standard triple therapy has declined to less than 80%. to overcome such alarming antibiotic resistance, antimicrobial susceptibility-guided therapy is recommended. however, the literature on gastric juice pcr as susceptibility-guided therapy is scant; therefore, the investigators conducted this prospective randomized controlled trial with the aim of investigating the efficacy of antibiotic susceptibility-guided therapy via gastric juice pcr for first-line eradication.

Eligibility criteria:
inclusion criteria: 1. male or non-pregnant female aged more than 20 yeasrs 2. h.pylori infection 3. mental and legal ability to give a written infomed consent exclusion criteria: 1. pregnant women 2. previous allergic reaction to antibiotics (clarithromycin, amoxicillin, levofloxacin, metronidazole and proton-pump inhibitor(rabeprazole) 3. patients with previous gastric surgery 4. the coexistence of serious concomitant illness(for example, decompensated liver cirrhosis, uremia)

Keywords: gastric juice guided therapy h.pylori eradication
training of cross-cultural competencies in psychotherapists

Conditions: Healthy Volunteers

Summary: the purpose of this study is to determine whether a web-based training program with text-based information as well as practical exercises can improve cross-cultural competencies in therapists.

as the number of patients from diverse cultures increases in psychotherapeutic care, cross-cultural competencies of therapists become increasingly important. in particular, mental health care of patients with immigration background needs to be improved as studies show that these patients drop out of treatment more often and benefit less from therapy. in addition, patients with immigration background and refugees show higher prevalences in mental illnesses. nevertheless, evaluated training programs to improve cross-cultural competencies in psychotherapists are lacking. in particular, web-based training programs, which allow therapists to work time-flexible and at their own pace on a training, are, to date, missing completely. for the current study, a web-based training program to improve therapists' cross-cultural competencies was developed. it is based on existing conceptions of cross-cultural competencies. the developed program consists of six modules with the following contents: definitions and conceptions of culture, the role of cross-cultural competencies in psychotherapy, the influence of prejudices and discrimination as well as the role of migration and acculturation, and culturally sensitive diagnostics. the modules contain pdf-files with text-based information, video files, case studies with associated questions as well as practical exercises. the main focus of the training is the participants' self-reflection concerning their conceptions of (their own) culture and their beliefs about culturally diverse patients. the training group will be compared to two other groups, i.e. an education only and a waitlist control group. whereas the waitlist control group will not receive any training materials, the education only group will receive a slimmed down version of the training consisting only of text-based information files.

Eligibility criteria:
inclusion criteria: * current psychotherapeutic work * internet access * sufficient german language skills * ongoing or completed training in psychotherapy exclusion criteria: * too much previous knowledge about cross-cultural competencies (\> 10h training)

Keywords: cross-cultural competencies internet-based training cognitive-behavioural therapy (cbt) psychotherapy training competence training
percutaneous needle electrolysis versus surgery in the treatment of carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the aim of this study is to compare the effectiveness of percutaneous needle electrolysis (pne) versus surgical treatment in the treatment of carpal tunnel syndrome (cts).


Eligibility criteria:
inclusion criteria: * over 18 years. * cts diagnosed by electromyography (emg) * symptoms of cts + emg exclusion criteria: * difficulty expressing your feelings properly * unsurpassed fear of needles * history of adverse reactions to needles * epilepsy and / or allergies to metals. * difficulty expressing your feelings properly * existence of diffuse peripheral neuropathy or cervical radiculopathy * history of potential concurrent cause of idiopathic cts (such as diabetes, thyroid, chronic rheumatoid arthritis, renal failure with hemodialysis, pregnancy..)

Keywords: carpal tunnel syndrome nerve compression syndrome median nerve physical therapy technique percutaneous needle electrolysis
different efficacy between rehabilitation therapy and stem cells transplantation in patients with sci in china

Conditions: Spinal Cord Injury

Summary: the morbidity of spinal cord injury (sci) is increasing year by year significantly in china. the methods to treat sci patients in sequela stage update are poor. though traditional rehabilitation therapy is the routine method to treat sci in sequela stage, aiming to improve the neurological disorders of these patients, such as sensory disturbance, dyskinesia, autologous adjustment of blood pressure, dysfunction of urination, defecation and perspiration , etc. what's a pity, the efficacy of the rehabilitation therapy is unsatisfactory. rehabilitation therapy can prevent the process of muscle atrophy and joint stiffness. however, it can not repair the damaged nerve function. studies show that mesenchymal stem cell transplantation can remarkably improve the neurological function of sci in animals without any severe side effect. in this study, 300 patients will be divided into three groups and the investigators will use mesenchymal stem cells derived from umbilical cord to treat 100 sci patients. they will also follow up 100 patients who only receive rehabilitation and another 100 patients who accept neither stem cell therapy nor rehabilitation. on this basis, the investigators can compare the efficacy of these two treatments.

patients enrolled in this study need to finish our whole follow-up survey, which is carried out by clinical doctors and epidemiologist.

Eligibility criteria:
inclusion criteria: 1. patients or their curator must be able to give voluntary consent. 2. patients have clear history of traumatic injury. 3. 20 years - 65 years of age can be enrolled. 4. both male and female can be enrolled. 5. the diagnosis of spinal cord injury are confirmed by all of the examinations including mri, electromyogram and electrophysiology. 6. the time of injury was longer than 1 year. exclusion criteria: 1. mental disorders 2. myelitis 3. women in pregnancy 4. cancer

Keywords: spinal cord injury cell transplantation rehabilitation
a study to assess the efficacy and safety of tc-5214 as an adjunct therapy in patients with major depressive disorder

Conditions: Major Depressive Disorder; Depression

Summary: the purpose of this study is to determine if tc-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.


Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent before initiation of any study-related procedures. * the patient must have a clinical diagnosis of major depressive disorder (mdd) with inadequate response to no more than one antidepressant. * outpatient status at enrollment and randomization. exclusion criteria: * patients with a lifetime history of bipolar disorder, psychotic disorder or post-traumatic stress disorder. * patients with a history of suicide attempts in the past year and/or seen by the investigator as having a significant history of risk of suicide or homicide. * history of renal insufficiency or impairment or conditions that could affect absorption or metabolism of investigational product.

Keywords: major depressive disorder mdd depression safety add-on therapy
umbilical cord mesenchymal stem cell treatment for crohn's disease

Conditions: Crohn Disease

Summary: stem cell transplantation has emerged as a relatively popular treatment that can help to regulate immunity, repair injury, and control inflammation. several studies have used autologous stem cells or adipose-derived stem cells to treat crohn's disease and its associated complications, and have achieved good efficacy. thus far, the use of umbilical cord mesenchymal stem cells (uc-mscs) to treat crohn's disease has rarely been reported. in this study, uc-mscs were used to treat patients with hormone-controlled crohn's disease. we observed the disease control conditions, corticosteroid dosage changes, and treatment-related adverse reactions.


Eligibility criteria:
inclusion criteria: * above 18 years of age * moderate to severe crohn's disease (crohn's disease activity index (cdai) between 220 and 450) * had received hormone maintenance therapy for more than 6 months exclusion criteria: * active tuberculosis * malignancy * hiv * syphilis * hepatitis b * hepatitis c
safety of cultured allogeneic adult umbilical cord derived mesenchymal stem cell intravenous infusion for ibd

Conditions: Inflammatory Bowel Diseases

Summary: this trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of inflammatory bowel disease

studies have shown that stem cell treatment is safe and efficacious for the treatment of inflammatory bowel disease (ibd). patients with ibd will receive a single intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells. the total dose will be 100 million cells. patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy. for patients with more severe disease requiring chemotherapeutic drugs such as methotrexate, an autologous t cell vaccine will be utilized created from the patient's own t cells obtained by apheresis

Eligibility criteria:
inclusion criteria: * diagnosis of crohn's disease or ulcerative colitis * understanding and willingness to sign a written informed consent document exclusion criteria: * active infection * active cancer * chronic multisystem organ failure * pregnancy * clinically significant abnormalities on pre-treatment laboratory evaluation * medical condition that would (based on the opinion of the investigator) compromise patient's safety. * continued drug abuse * pre-menopausal women not using contraception * previous organ transplant * hypersensitivity to sulfur

Keywords: ibd inflammatory bowel diseases stem cell treatment
to evaluate safety and efficacy of nuvastatic as an immunomodulator adjuvant therapy in covid-19 patients.

Conditions: Covid19

Summary: a two arm open label multi-centered randomized interventional trial is proposed to assess aspects of safety and efficacy of nuvastatic™ (serial no: c5osew5050esa) . two parallel groups of (1:1) ratio comparing nuvastatic™ versus standard care will be conducted on patients on oxygen saturation (sao2) of 94% or less while they are breathing ambient air or a ratio of the partial pressure of oxygen (pao2) to the fraction of inspired oxygen (fio2) (pao2:fio2) at or below 300 mg hg. primary outcome measures: time to clinical improvement, defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever comes first. secondary outcome measures: clinical status as assessed with the seven-category ordinal scale on days 7 and 14, mortality at day 28. 1. the duration of mechanical ventilation. 2. the duration of hospitalization in survivors. 3. the time (in days) from treatment initiation to death. 4. virologic measures included the proportions with viral rna detection over time and viral rna titer area under-curve (auc) measurements.

this study will propose nuvastiatic™ as a new lead therapeutic agent for sars-cov-2, and new insights for currently ongoing clinical trials to treat sars-cov-2 infections. nuvastatic™ could be used as potential anti-coronavirus therapy that acts on the human immune system or human cells as an immune modulator, and the other on coronavirus itself as an antiviral agent. in terms of the human immune system, the innate immune system response plays an important role in controlling the replication and infection of coronavirus, and interferon gamma, interleukins, th cells, granulocyte macrophage are expected to enhance the immune response.

Eligibility criteria:
inclusion criteria: 1. male and nonpregnant female patients 18 years of age or older eligible if they had a diagnostic specimen that was positive on rt-pcr. - 2. for mild - moderate cases: subjects who show positive for nasal swab test at screening using rt-pcr protocol for covid 19. 3. for severe cases - has an oxygen saturation (sao2) of 94% or less while they are breathing ambient air or a ratio of the partial pressure of oxygen (pao2) to the fraction of inspired oxygen (fio2) (pao2:fio2) at or below 300 mg hg. 4. ability to understand and the willingness to sign a written informed consent document. exclusion criteria: 1. female subjects who are pregnant or breastfeeding. 2. patients who are allergic to this medicine 3. patients allergic to content of study product 4. patients with diabetes. 5. patients accompanied by serious physical diseases of heart, lung, brain, etc. 6. patients have any condition that in the judgement of the investigators would make the subject inappropriate for entry into this study. 7. patients who are not able to take drugs orally.
ashwagandha for cognitive dysfunction

Conditions: Chemo Fog

Summary: this is a 1:1 randomized double blinded placebo controlled trial. • to determine if ashwagandha can improve cognitive dysfunction when compared with placebo in patients undergoing chemotherapy for cancer.

patients are eligible if they are currently undergoing chemotherapy or treatment with chemotherapy in the past year and state that they notice thinking or memory problems. patients will be given fact-cog pci (version 3). patients that score less than 63, a score that reflects moderate to severe cognitive problems, are confirmed eligible. subjects will be randomized 1:1 in blocks of 4. thyroid hormone testing will be conducted at baseline and at the end of week 6 for patients with a history of thyroid disease. patients will receive ashwagandha 350 mg po bid or placebo. the investigators and participants will be blinded to group assignment. endpoint testing including the fact-cog pci and total score, hopkins verbal learning test, trail making test (abstraction and executive function), and mini mental status exam (mmse) will be administered at baseline and after 9 weeks of treatment. six months after stopping the study, patients will receive a link to a redcap database to complete the fact-cog and state whether they used ashwagandha once they completed the study. active study participation will be for 9 weeks.

Eligibility criteria:
inclusion criteria: 1. age 18 years and older 2. english speaking 3. currently undergoing chemotherapy or treatment with chemotherapy in the past year 4. self-reported memory loss, attention, visual-spatial functioning, reasoning, or information processing or cognitive changes in the first 2 cycles of chemotherapy and score \< 63 on the fact-cog pci 5. able to follow instructions for testing and comply with testing 6. able to swallow pills exclusion criteria: 1. undergoing treatment for any hormone dependent cancer 2. planned surgical treatment 3. history of pre-existing dementia, untreated depression, psychiatric disorder, prior brain radiation or brain injury 4. history of hypotension 5. active autoimmune disease 6. brain metastasis 7. taking any drugs daily that would alter cognition 8. concurrent use of benzodiazepenes or other sedatives 9. concurrent use of supplements that can cause sedation such as 5-htp, calamus, california poppy, hops, jamaican dogwood, kava, st.john's wort, skullcap, valerian, yerba mansa 10. currently taking hypoglycemic medications 11. history of substance abuse 12. current or recent diagnosis of stomach ulcer or gastritis

Keywords: ashwagandha cognitive dysfunction cancer chemotherapy
effect of pre-emptive dose of prednisone versus placebo in impacted third molar surgery

Conditions: Facial Swelling; Tooth Position Anomalies; Tooth, Impacted; Tooth Extraction Status Nos; Tooth Avulsion

Summary: the present study proposes to compare the effect of a single preoperative dose of prednisone versus placebo in terms of facial swelling, trismus and pain after surgical removal of the mandibular third molar (m3m) in a split-mouth randomized controlled clinical trial.

this study aims to compare the effect of a single preoperative dose of prednisone versus placebo in terms of facial swelling, trismus, and pain after surgical removal of m3m in a split-mouth randomized controlled clinical trial. facial swelling will be evaluated using an innovative three-dimensional digital technique.

Eligibility criteria:
inclusion criteria: * patients aged 18 to 32 years who required both m3m extractions were recruited * good health status * indication to surgical extraction of both m3m * complete root formation * surgical risk level classified as "conventional" or "moderate" according to daugela et al. classification exclusion criteria: * person under the age of 18 or over 32 * allergy or contraindications to administration of corticosteroids * acute infection in any of the teeth to be extracted * patients with chronic liver disease, diabetes, immune system dysfunction, or haematological disease * pregnancy or breastfeeding * history of treatment with antiresorptive drugs * chronic kidney disease * history of systemic corticosteroid therapy in the past 4 weeks

Keywords: third molar surgery facial swelling 3d facial swelling evaluation tooth impacted prednisone drug administration corticosteroids administration
danalysis of the distribution of adrenal steroids in a control population

Conditions: Adrenal Disease

Summary: this is a biomedical research study on the determination of adrenal steroids. it has been proposed in recent years as a tool for the diagnostic orientation of an adrenal pathology. the main objective is to analyze the distribution of blood and urinary adrenal steroid values in a population of 60 controls. the secondary objective is to establish reference values for each of these parameters, if their distribution permits, and to study the possible link between the blood pressure level, the orthostatism state, the potassium level and these adrenal steroids.


Eligibility criteria:
inclusion criteria: * negative blood pregnancy test * normosalt diet * men and women ≥ 18 years * being able and willing to give written informed consent exclusion criteria: * personal history of diabetes, high blood pressure, adrenal pathologies. * family history of adrenal pathologies. * taking of the following drugs: antihypertensives drugs: ace inhibitor, angiotensin ii receptor, beta-blocker, thiazide diuretic, loop diuretic, anti-aldosterone, dihydropyridine-type calcium antagonist. * hormone replacement therapy, cyproterone acetate * nsaid (except occasional intake), corticosteroid * antidepressant: serotonin reuptake inhibitor (paroxetine, fluoxetine, sertraline, citalopram) * contraception or estrogen / progestin treatment (progestins only allowed) * not be able to keep standing position.

Keywords: adrenal steroids mass spectroscopy liquid chromatography
a study of mircera in anemic patients with multiple myeloma

Conditions: Anemia

Summary: this study will investigate the efficacy, safety and pharmacokinetics of mircera in adult anemic patients with multiple myeloma. in the first stage of the study, patients will be randomized to receive subcutaneous injections of mircera once every 3 weeks, at doses of 2.0, 3.5 or 5.0 micrograms/kg. following the administration of 2 doses, an evaluation of hemoglobin increase will be made at week 6. in the second stage, further groups of patients will receive additional doses of mircera,at doses of 1.0, 6.5 or 8.0 micrograms/kg, depending on efficacy, safety and pharmacokinetic considerations.the anticipated time on treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * confirmed diagnosis of multiple myeloma; * anemia (hemoglobin \<=11g/dl at screening visit). exclusion criteria: * transfusion of red blood cells during 2 months prior to first planned dose of study medication; * therapy-resistant hypertension; * relevant acute or chronic bleeding within 3 months prior to planned start of study treatment; * recombinant human erythropoietin or erythropoiesis-stimulating drug therapy within 3 months prior to planned start of study treatment.